CONFIDENTIAL TREATMENT REQUESTED
Exhibit 10.2
CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***].”
.OMB Approval 2700-0042
| AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT |
1. CONTRACT ID CODE |
PAGE OF PAGES | ||||
| N/A | 1 | 2 | ||||
|
2. AMENDMENT/MODIFICATION NO. 0009 |
3. EFFECTIVE DATE [See block 16C, below] |
4. REQUISITION/PURCHASE REQ. NO
|
5. PROJECT NO. (If applicable) N/A | |||||||
| 6. ISSUED BY | CODE | 7. ADMINISTERED BY (IF OTHER THAN ITEM 6) | CODE | N/A
| ||||||
|
National Institutes of Health National Institute of Allergy and Infectious Diseases DEA, Office of Acquisitions Room 3B49, MSC 9821 5601 Fishers Lane Bethesda, MD 20892-9821
|
MID RCB-B | |||||||||
|
8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State, and Zip Code) Pfenex, Inc. 10790 Roselle Street San Diego, CA 92121 |
☐ |
9A. AMENDMENT OF SOLICITATION NO.
| ||||||
|
9B. DATED (SEE ITEM 11)
| ||||||||
|
☒ |
10A. MODIFICATION OF CONTRACT/ORDER NO. HHSN272201200033C
| |||||||
| CODE:
| FACILITY CODE:
|
10B. DATED (SEE ITEM 13) 09/27/2012
| ||||||
| 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS | ||||||||
☐ The above numbered, solicitation is amended as set forth in item 14. The hour and date specified for receipt of Offers ☐ is extended ☐ is not extended.
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one of the following methods:
(a) By completing Items 8 and 15, and returning one (1) copy of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers, FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
| 12. ACCOUNTING AND APPROPRIATION DATA (If Required) | ||
| 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS, IT MODIFIES THE CONTRACT/ORDER NO., AS DESCRIBED IN ITEM 14 | ||
| ☐ | A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify Authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
| |
| ☐ | B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43,103 (b).
| |
| ☒ | C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: Mutual Agreement of the Parties
| |
| ☐ | D. OTHER (Specify type of modification and authority)
| |
| E. IMPORTANT: Contractor ☐ is NOT ☒ is required to sign this document and return 1 copies to the issuing office. | ||
| 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) | ||
| PURPOSE: The purpose of this modification is to update ARTICLE G.2. Key Personnel.
| ||
| TOTAL FUNDS CURRENTLY OBLIGATED: $[***] TOTAL ESTIMATED COST: $[***] | FUNDED THROUGH DATE: December 31, 2017 (Unchanged) COMPLETION DATE: December 31, 2017 (Unchanged) | |
|
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.
| ||
| 15A. NAME AND TITLE OF SIGNER | 16A. NAME AND TITLE OF CONTRACTING OFFICER Michael P. Welsh Contracting Officer, MID RCB-B, OA, DEA, NIAID, NIH, DHHS
| |||||
| 15B. CONTRACTOR/OFFEROR
/s/ Patrick Lucy (Signature of person authorized to sign) | 15C. DATE SIGNED 9/27/16 | 16B. UNITED STATES OF AMERICA
/s/ Michael P. Welsh (Signature of Contracting Officer)
| 16C. DATE SIGNED 9/28/16 | |||
| NSN 7540-01-152-8070 | 30-105 | STANDARD FORM 30 (REV. 10-83) | ||
| Previous Edition Unusable | Computer Generated | Prescribed by GSA | ||
| FAR (48 CFR) 53.243 |
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
|
Contract No: HHSN272201200033C
|
Modification No: 09
|
Page 2 of 2
|
ARTICLE G.2. KEY PERSONNEL (HHSAR 352.242-70 (January 2006) is hereby modified to update key personnel as follows:
| Name | Title | |
| [***] | Principal Investigator | |
| [***] | Deputy Principle Investigator | |
| [***] | Clinician focused on pre-clinical and clinical studies | |
| [***] | Director Downstream Processing (DSP) and Analytical Biochemistry | |
| [***] | Project Manager | |
| [***] | Project Control Manager |
HHS-556
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
